Key Highlights

  • Intellia Therapeutics (NASDAQ:NTLA) shares climbed 6.57% to USD 10.15 on November 20, 2026.
  • The FDA set a March 10, 2027 decision date for lonvo-z.
  • Cash and securities were USD 614.8 million at September 30, 2026.
  • Third quarter net loss was USD 127.5 million.

A Gene-Editing Stock Rises Toward a Regulatory Deadline

Intellia Therapeutics (NASDAQ:NTLA), a Cambridge, Massachusetts company that develops CRISPR gene-editing medicines, climbed 6.57% to USD 10.15 on November 20, 2026. The move sits against a clear regulatory calendar. In September 2026 the FDA accepted the company's Biologics license application for lonvo-z, a one-time treatment for hereditary angioedema, and granted it priority review. The agency set a decision date of March 10, 2027 and said it does not currently plan to hold an advisory committee meeting. If approved, lonvo-z would be the first in vivo CRISPR-based therapy, meaning the editing happens inside the patient's body, and the only one-time treatment for the condition. Launch is planned for the first half of 2027. A rise like this one can reflect traders positioning ahead of a binary event, which can reverse quickly if sentiment changes before the decision arrives.

Phase 3 Data and a Cash Runway Into 2028

The application rests on the Phase 3 HAELO trial, which enrolled 80 patients in nine months and tested a single 50 milligram dose. As of the data cutoff, every patient who received lonvo-z at baseline or after crossing over from placebo remained free from long-term prophylaxis therapy. No serious adverse events were seen in the lonvo-z arm. The Balance Sheet matters for a company with no marketed product. Cash, cash equivalents and marketable securities were USD 614.8 million at September 30, 2026, down from USD 628.4 million at June 30. Management expects that cash to fund operations at least into 2028, beyond the planned launch. An April 2026 stock offering raised about USD 195 million in net proceeds, and additional Loan tranches of up to USD 225 million can be drawn at the company's option if it meets lonvo-z milestones. New share sales can dilute existing holders.

Widening Losses and the Nex-z Safety Overhang

Third quarter results reported on November 5, 2026 showed the cost of building toward a launch. Net loss was USD 127.5 million, up from USD 101.3 million a year earlier, and the loss per share of USD 0.91 was wider than the USD 0.82 that analysts expected. Collaboration Revenue dropped to USD 7.2 million from USD 13.8 million, mainly because of lower revenue from Regeneron (NASDAQ:REGN), the partner on nex-z. Nex-z, the company's candidate for transthyretin amyloidosis, remains the larger source of risk. Its Phase 3 studies were halted after a serious liver event and a clinical hold, and enrollment has since restarted, with the MAGNITUDE-2 trial now fully enrolled. A second safety event would hurt the whole platform, not only the program involved. Intellia is scheduled to appear at investor conferences in December.

Where Things Stand

Intellia Therapeutics (NASDAQ:NTLA) climbed 6.57% because investors are positioning ahead of the March 10, 2027 FDA decision on lonvo-z, a priority-review application backed by Phase 3 data, with a cash runway into 2028. The risks are a widening net loss of USD 127.5 million, falling collaboration revenue and the unresolved safety history of nex-z. For a stock with no marketed product, a regulatory decision or a safety event can move the shares far more than any single trading day. The shares trade on a US exchange, so the move came in the US session.